The rational method for choosing supplementation is to measure before supplementing. A blood panel targeting five biomarkers (25-OH-D, ferritin, red blood cell magnesium, vitamin B12, and hs-CRP) identifies an individual's actual needs before any nutrient is taken. Twenty years of accumulated literature show that standardized supplementation, applied to populations not stratified by baseline biomarkers, produces on average null effects on mortality, sometimes negative. The question is therefore not "which supplement to take" but "what is my biology".
The biomarker-first approach inverts the prevailing commercial logic. It does not start from a product looking for a target population. It starts from an individual biological profile and deduces the appropriate formula.
Why blind supplementation fails
The first myth to dismantle is that of universal benefit. Supplementing an entire population with a given nutrient, without measuring baseline status, almost always produces a disappointing average result. The VITAL trial, conducted on 25,871 American adults with 2,000 IU of vitamin D3 daily for more than five years, showed no significant reduction in major cardiovascular events or invasive cancers compared with placebo (PubMed). This result does not invalidate vitamin D. It invalidates the strategy of supplementation without baseline 25-OH-D stratification.
Vitamin E tells a darker story. The SELECT trial followed 35,533 healthy men on 400 IU of vitamin E daily. The supplemented group showed a significant increase in prostate cancer risk compared with placebo (PubMed). Giving a supraphysiological antioxidant dose to a population without documented deficiency can cause harm.
The reference meta-analysis of vitamin D and total mortality, covering 18 randomized trials and 57,311 participants, shows a modest effect (RR 0.93) that often disappears when baseline status is ignored (PubMed). The signal appears only in initially deficient individuals. For others, the effect tends toward zero.
The lesson is consistent. A nutrient has a demonstrated effect only when it addresses a pre-existing need. This is the central idea developed in our article The Multivitamin Myth: applying the same dose to everyone means accepting to be either underdosed or overdosed, rarely right on target.
The five biomarkers to test before any supplementation
Five blood tests cover the essential nutritional terrain for an apparently healthy adult. They do not replace a complete workup, but they guide around eighty percent of common supplementation decisions.
1. 25-hydroxyvitamin D (25-OH-D)
The main circulating form of vitamin D, a faithful reflection of body stores. Individual needs vary by a factor of one to ten depending on skin pigmentation, fat mass, sun exposure, and latitude of residence (PubMed). The optimal zone lies between 40 and 60 ng/mL for most laboratories. Below 30 ng/mL, insufficiency is likely. Below 20 ng/mL, it is certain (PubMed).
This test directly guides the dose of vitamin D3. An individual at 15 ng/mL in winter needs a far higher daily dose than one at 45 ng/mL in summer. See the detailed page Vitamin D (25-OH-D).
2. Ferritin
The primary marker of iron stores. Low ferritin (typically below 30 µg/L per WHO thresholds) indicates a nutritional iron need, even without overt anemia. A classic pitfall: ferritin is also an acute-phase protein that rises with inflammation or overweight. In people with excess body weight, normal or elevated ferritin can mask a functional iron deficit (PubMed). This is why it should always be read alongside hs-CRP.
This biomarker is critical before any intake of iron. Iron supplementation in an already overloaded individual is pro-oxidant and raises hepatic risk. See Ferritin.
3. Red blood cell magnesium
Serum magnesium is still the default test in most laboratories. It is a mistake. Serum magnesium represents only 1% of total body magnesium and remains within range even with a pronounced intracellular deficit (PubMed). Red blood cell magnesium (measured inside erythrocytes) reflects tissue stores and is a more reliable biomarker of true magnesium status (PubMed).
The erythrocyte variant must be requested explicitly. The desirable zone is between 1.65 and 2.65 mmol/L depending on the reference. Below that, a magnesium supplement in a bioavailable form (bisglycinate, malate, threonate) becomes relevant. See Magnesium.
4. Vitamin B12
The standard serum B12 assay lacks sensitivity and specificity. An individual can have a "normal" serum B12 and a documented functional deficit revealed by elevated methylmalonic acid (MMA) or homocysteine (PubMed). Commonly used diagnostic thresholds underestimate needs, particularly in individuals over 50, strict vegetarians, people on metformin, or on proton pump inhibitors.
A B12 below 300 pg/mL justifies MMA testing to confirm. When deficiency is confirmed, supplementation with vitamin B12 as methylcobalamin or hydroxocobalamin restores status within weeks. See Vitamin B12.
5. hs-CRP (high-sensitivity C-reactive protein)
hs-CRP is not a direct nutritional marker: it is the inflammatory thermostat. Its reference thresholds, established in large cardiovascular cohorts, stratify risk into three zones (below 1 mg/L: low, 1 to 3 mg/L: intermediate, above 3 mg/L: high) (PubMed). An elevated hs-CRP radically changes the interpretation of other markers (ferritin and B12 in particular) and points toward bioactives targeting inflammatory modulation (omega-3, magnesium, polyphenols) rather than standard supplementation.
It completes the picture by locating the individual on their baseline inflammatory axis. See hs-CRP.
A panel of 25-OH-D, ferritin, red blood cell magnesium, vitamin B12, and hs-CRP covers the essential supplementation decisions for an apparently healthy adult.
Reading your panel: what each value says about needs
Having the numbers is not enough. Interpretation drives the formula. Four reading angles structure the analysis.
Vertical reading. Each biomarker has a reference range, an insufficiency zone, and an optimal zone. The reference range (defined on a general population) is not the optimal zone. Many laboratories flag vitamin D as "normal" from 20 ng/mL onward, while the research literature places the optimum above 40 ng/mL. The same gap exists for ferritin, B12, and magnesium. Settling for reference bounds means accepting statistical mediocrity as a target.
Cross reading. A biomarker taken alone can mislead. A ferritin at 90 µg/L with hs-CRP at 5 mg/L likely signals inflammation masking a worse iron status than it appears. A serum B12 at 350 pg/mL with homocysteine at 14 µmol/L suggests a functional deficit despite apparent normality. It is the combination that informs, not the isolated value, as analyzed in our article on homocysteine.
Longitudinal reading. A one-off value is a snapshot. Two values three months apart reveal a trajectory. It is the trajectory that matters when judging supplementation effectiveness and adjusting doses. Without a retest, no protocol is calibrated.
Contextual reading. Needs vary with age, biological sex, physical activity, pregnancy, medications, and chronic conditions. An endurance athlete has above-average iron and magnesium needs. A patient on a proton pump inhibitor absorbs B12 poorly. A strict vegetarian has virtually no dietary B12 intake. A panel only makes sense within that context.
Classic supplementation pitfalls
Once the biomarkers are read, three major pitfalls remain on the product side.
Proprietary blends. Formulas labeled "proprietary blend" or "exclusive complex" hide individual doses behind a total dose. There is no way to know whether you are getting 10 mg or 500 mg of a given bioactive. That opacity disqualifies the product. Any serious formula lists every individual dose in milligrams, with the precise chemical form. This is the absolute-dose illusion analyzed in our dedicated article.
Poorly bioavailable forms. Not all forms of a given nutrient are equal. Magnesium oxide is absorbed at less than 5%, while bisglycinate exceeds 40%. Ferrous sulfate often causes digestive upset where iron bisglycinate is better tolerated. Cyanocobalamin (synthetic B12) is less effective than methylcobalamin in individuals carrying certain genetic polymorphisms. The chemical form drives real-world efficacy.
Nutrient antagonisms. Some nutrients interfere with each other. Calcium at high doses (300 to 600 mg) reduces iron absorption by 50 to 60% when taken at the same meal (PubMed). Zinc and copper compete: prolonged zinc supplementation without copper creates an imbalance. Iron and zinc share the same intestinal transporters. The timing of intake matters as much as the doses. This subject is developed in the article on supplement interactions.
The rational sequence: measure, interpret, calibrate
Any rational supplementation follows three steps, always in this order.
Measure. An initial blood panel centered on the five key biomarkers, optionally expanded based on profile (homocysteine, copper, zinc, selenium, erythrocyte omega-3). This is the minimum investment. Without data, no nutritional decision is rational.
Interpret. Read the values in their optimal zones (not just reference zones), cross them against each other, place them in the individual context (age, sex, diet, activity, medications). This step defines real needs, ordered by priority.
Calibrate. Choose the bioactives, their bioavailable forms, their individualized doses, and their timing to avoid antagonisms. Schedule a retest at three or six months to verify the trajectory and adjust.
This sequence is also what distinguishes precision supplementation from standard supplementation, as analyzed in our comparison Multivitamin vs personalized supplementation.
Conclusion: inverting the question
The common question "which supplements should I take" is poorly framed. It starts from the product, looks for a generic need, and sells a standardized dose. That is the economics of mass-market supplementation.
The rational question is different. "Where is my biology, where are my insufficiencies, which forms and doses address them most effectively." It starts from the body, identifies real needs, and deduces the appropriate bioactives. It imposes a detour through measurement. It costs an initial blood panel. It then avoids years of unnecessary or counterproductive supplementation.
The best supplement does not exist in the abstract. It exists for a given profile, at a given moment, at a given dose. Everything else is approximation.
Frequently asked questions
References
- Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44. (PubMed)
- Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556. (PubMed)
- Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730-1737. (PubMed)
- Papadimitriou DT. The Big Vitamin D Mistake. J Prev Med Public Health. 2017;50(4):278-281. (PubMed)
- Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. (PubMed)
- Khan A, Khan WM, Ayub M, et al. Ferritin Is a Marker of Inflammation rather than Iron Deficiency in Overweight and Obese People. J Obes. 2016;2016:1937320. (PubMed)
- Costello RB, Nielsen F. Interpreting magnesium status to enhance clinical care: key indicators. Curr Opin Clin Nutr Metab Care. 2017;20(6):504-511. (PubMed)
- Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnes Res. 2011;24(4):163-180. (PubMed)
- Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-160. (PubMed)
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979. (PubMed)
- Hallberg L, Brune M, Erlandsson M, Sandberg AS, Rossander-Hultén L. Calcium: effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr. 1991;53(1):112-119. (PubMed)
